| Document |
Document Title |
|
WO/2023/195529A1 |
The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...
|
|
WO/2023/195669A1 |
The present invention relates to a novel benzothiophene derivative and use thereof as a bromodomain extra-terminal (BET) inhibitor, and, more specifically, to a novel benzothiophene derivative compound of the following chemical formula 1...
|
|
WO/2023/195787A1 |
An organic compound represented by chemical formula 1 of the present invention can implement excellent hole transfer characteristics. In addition, at least one of a hole transport layer and a hole transport aid layer of an organic light ...
|
|
WO/2023/194458A1 |
The present invention relates to a compound of formula (I) or an enantiomer, diastereomer, N-oxide, solvate or pharmaceutically acceptable salt thereof. The present invention further relates to a compound of formula (I) for use in a meth...
|
|
WO/2023/195791A1 |
The present invention relates to a phenylpropenone backbone compound, which is a novel chromanone or a ring-opened form thereof, and a composition for preventing or treating multiple myeloma comprising same as an active ingredient. The c...
|
|
WO/2023/191353A1 |
The present specification relates to a heterocyclic compound of chemical formula 1, an organic light-emitting device comprising same, and a composition comprising same for forming an organic layer.
|
|
WO/2023/185078A1 |
The present invention relates to an organic compound, an electronic element and an electronic device. The structure of the organic compound is as shown in formula 1, and the organic compound can improve the performance of an electronic e...
|
|
WO/2023/191536A1 |
The present invention relates to a thiobenzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer, the composition comprising the derivative as an active ingredient. The th...
|
|
WO/2023/186023A1 |
The present invention belongs to the field of pharmaceutical chemistry. Specifically disclosed are a N-substituted quinolinone compound, a preparation method therefor and pharmaceutical use thereof. The compound of the present invention ...
|
|
WO/2023/191468A1 |
The present invention relates to nitrogen-containing heterocyclic compound derivatives and uses thereof. The compounds according to the present invention can exert therapeutic effects on various neurological disorders, such as neurodegen...
|
|
WO/2023/190987A1 |
Provided are: a compound represented by either formula (1) or formula (2) (where the symbols in formula (1) and formula (2) are as defined in the description); an organic electroluminescent element containing the compound; and an electro...
|
|
WO/2023/192578A1 |
The present invention relates to novel bifunctional compounds, as well as compositions thereof, which modulate KLHDC2 and/or function to recruit targeted proteins to KLHDC2 for degradation. These bifunctional compounds, which find utilit...
|
|
WO/2023/192506A1 |
Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.
|
|
WO/2023/191469A1 |
The present invention relates to nitrogen-containing heterocyclic compounds having a phenyl group and uses thereof. The compounds, according to the present invention, effectively enhance synaptic plasticity without side-effects and thus ...
|
|
WO/2023/182899A1 |
The present invention relates to a novel compounds for use in treatment or prevention of cancer, in particular to use of said compounds as an inhibitors of interactions between TRF1-TIN2 or TRF2-TIN2 telomeric proteins.
|
|
WO/2023/179094A1 |
The present application relates to an organic compound, and an electronic component and an electronic device comprising same. The structural formula of the organic compound of the present application is shown as formula 1, the organic co...
|
|
WO/2023/182897A1 |
The present invention relates to a novel compounds for use in treatment or prevention of cancer, in particular to use of said compounds as an inhibitors of interactions between TRF1-TIN2 or TRF2-TIN2 telomeric proteins.
|
|
WO/2023/182836A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/179758A1 |
Disclosed in the present application is a crystal of a fused tricyclic derivative or a pharmaceutically acceptable salt thereof; and specifically disclosed are a crystal of a compound of formula (I), a crystal of a pharmaceutically accep...
|
|
WO/2023/182775A1 |
The present invention pertains to: a novel aromatic heterocyclic compound that can be used in an organic light-emitting diode; and an organic light-emitting diode including same.
|
|
WO/2023/176609A1 |
This composition includes an infrared absorbing agent, a curable compound, and a solvent, wherein the infrared absorbing agent includes a compound represented by formula (1). Provided are a film, an optical filter, a solid-state imaging ...
|
|
WO/2023/177184A1 |
The present invention relates to: a compound, represented by chemical formula 1, for an organic optoelectronic device; an organic optoelectronic device comprising same; and a display device. The details of chemical formula 1 are as defin...
|
|
WO/2023/174235A1 |
Disclosed are a compound represented by formula (I) as a mutant isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) inhibitor, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed is a use of the described...
|
|
WO/2023/176957A1 |
The present invention provides a compound which is used for the treatment of a fungal infection, including a topical fungal infection and a systemic fungal infection, caused by fungi belonging to the genus Trichophyton, the genus Candida...
|
|
WO/2023/177568A1 |
The application relates to compounds of the general Formula (I) which act as cannabinoid receptor modulators useful for the treatment of complications arising from metabolic, inflammatory and fibrotic disorders.
|
|
WO/2023/170025A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compo...
|
|
WO/2023/169453A1 |
The present invention relates to a heteroaromatic ring-containing alkynyl compound, and a preparation method therefor and the use thereof. The heteroaromatic ring-containing alkynyl compound is a compound represented by a formula (I), or...
|
|
WO/2023/171788A1 |
The present invention addresses the problem of providing: a photoelectric conversion element which is excellent in production applicability and also excellent in photoelectric conversion efficiency; an imaging element; a photosensor; and...
|
|
WO/2023/168908A1 |
Disclosed are fused quinone oxime imidazole, an onium derivative thereof, a preparation therefor and a use thereof. The structure of the fused quinone oxime imidazole is represented by the following general formulas (I), (II), (III) and ...
|
|
WO/2023/171920A1 |
Provided is a high-refractive-index carbazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...
|
|
WO/2023/171934A1 |
The present invention relates to a novel organic compound and an organic light-emitting device comprising same. More specifically, the present invention provides an organic electroluminescent device which has low driving voltage and is s...
|
|
WO/2023/169436A1 |
Disclosed in the present invention are a benzo bicyclic compound, and a preparation method and application thereof. Specifically disclosed is a compound, which is a compound as shown in formula (X), or a stereoisomer, geometric isomer, t...
|
|
WO/2023/169481A1 |
The present invention provides a tetrahydroisoquinoline derivative as a pan-KRAS inhibitor. Specifically, the present invention provides a tetrahydroisoquinoline derivative having a structural formula as shown in general formula (I) and ...
|
|
WO/2023/168240A1 |
The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myoca...
|
|
WO/2023/165523A1 |
Disclosed in the present invention are an aromatic ring substituted methoxy derivative and a use thereof. The aromatic ring substituted methoxy derivative has a structure as shown in formula I, and is expected to be used for treating tum...
|
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/165403A1 |
A composition, an organic light-emitting device, and a display apparatus. The composition comprises at least two compounds each having a structure represented by formula I. By designing the components of the composition, further using to...
|
|
WO/2023/166067A1 |
A compound of Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2023/164358A1 |
The present application describes GLP-IR modulating compounds that are useful for treating GLP-IR-mediated diseases or conditions.
|
|
WO/2023/163140A1 |
The purpose of the present invention is to provide a compound that exhibits an H-PGDS inhibitory activity. The present invention relates to a compound expressed by formula [I] or a pharmaceutically acceptable salt thereof (in the formula...
|
|
WO/2023/163479A1 |
The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic materi...
|
|
WO/2023/161172A1 |
The present invention relates to substituted N-benzoic acid uracils of general formula (I) or salts thereof, wherein the radicals in general formula (I) correspond to the definitions given in the description, and to the use thereof as he...
|
|
WO/2023/161316A1 |
The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A, X, R1-R9, R12 and R13 are as described herein (I). Further provided are pharmaceutical ...
|
|
WO/2023/163381A1 |
The present specification relates to a heterocyclic compound of chemical formula 1, and an organic light-emitting device and an organic material layer formation composition which comprise same.
|
|
WO/2023/160121A1 |
The present application belongs to the technical field of organic materials. Provided are an organic compound, an electronic element comprising same, and an electronic device, wherein the organic compound has a structure as represented b...
|
|
WO/2023/164612A1 |
Disclosed herein are compounds (I) and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of d...
|
|
WO/2023/070987A9 |
Provided are an organic compound, an organic electroluminescent device comprising same, and an electronic apparatus, relating to the field of organic electroluminescence. The structure of the organic compound is as shown in formula 1, an...
|
|
WO/2023/155710A1 |
The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2022/129589A9 |
The present disclosure relates to novel compounds of formula (I) which are useful as inhibitors of endoplasmic reticulum aminopeptidases (ERAP), in particular as inhibitors of ERAP2. The disclosure also relates to the therapeutic use of ...
|
